Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
NHS England
Quarry House
Leeds
LS2 7UE
UK
Contact person: Philip Grieve
E-mail: philip.grieve@nhs.net
NUTS: UKE
Internet address(es)
Main address: https://www.england.nhs.uk//
Address of the buyer profile: https://www.england.nhs.uk//
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
Reference number: CM/PHS/19/5583
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. <br/>Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
II.1.6) Information about lots
This contract is divided into lots:
Yes
II.1.7) Total value of the procurement
Value excluding VAT:
198 666 666.00
GBP
II.2) Description
Lot No: 1
II.2.1) Title
Lot 1 – C1 Esterase – Recombinant IV (acute treatment)
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.5) Award criteria
Quality criterion: Security of Supply
/ Weighting: 20%
Quality criterion: Ease of Use
/ Weighting: 10%
Price
/ Weighting:
70%
II.2.11) Information about options
Options:
Yes
Description of options:
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot No: 2
II.2.1) Title
Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.5) Award criteria
Quality criterion: Security of Supply
/ Weighting: 20%
Quality criterion: Ease of Use
/ Weighting: 10%
Price
/ Weighting:
70%
II.2.11) Information about options
Options:
Yes
Description of options:
Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot No: 3
II.2.1) Title
Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.5) Award criteria
Quality criterion: Security of Supply
/ Weighting: 20%
Quality criterion: Ease of Use
/ Weighting: 10%
Price
/ Weighting:
70%
II.2.11) Information about options
Options:
Yes
Description of options:
Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot No: 4
II.2.1) Title
Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.5) Award criteria
Quality criterion: Security of Supply
/ Weighting: 20%
Quality criterion: Ease of Use
/ Weighting: 10%
Price
/ Weighting:
70%
II.2.11) Information about options
Options:
Yes
Description of options:
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot No: 5
II.2.1) Title
Lot 5 - Icatibant
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.5) Award criteria
Quality criterion: Security of Supply
/ Weighting: 20%
Quality criterion: Ease of Use
/ Weighting: 10%
Price
/ Weighting:
70%
II.2.11) Information about options
Options:
Yes
Description of options:
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot No: 6
II.2.1) Title
Lot 6 - Lanadelumab
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.5) Award criteria
Quality criterion: Security of Supply
/ Weighting: 20%
Quality criterion: Ease of Use
/ Weighting: 10%
Price
/ Weighting:
70%
II.2.11) Information about options
Options:
Yes
Description of options:
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot No: 7
II.2.1) Title
Lot 7 - Berotralstat
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.5) Award criteria
Quality criterion: Security of Supply
/ Weighting: 20%
Quality criterion: Ease of Use
/ Weighting: 10%
Price
/ Weighting:
70%
II.2.11) Information about options
Options:
Yes
Description of options:
Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.2.14) Additional information
Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2022/S 000-003602
Section V: Award of contract
Lot No: Lot 1 - C1 Esterase – Recombinant IV (acute treatment)
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 1 - C1 Esterase – Recombinant IV (acute treatment)
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Pharming Group
Darwinweg, The Netherlands
Darwinweg
242333
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 2
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 2
Number of tenders received by electronic means: 2
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
CSL Behring UK Ltd
4 Milton Road, Haywards Heath
Haywards Heath
RH16 1AH
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 2
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 2
Number of tenders received by electronic means: 2
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 3
Contract No: CM/PHS/19/5583
Title: Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 4
Contract No: CM/PHS/19/5583
Title: Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
CSL Behring UK Ltd
4 Milton Road, Haywards Heath
Haywards Heath
RH16 1AH
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 5
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Martindale Pharma
Building A2 Glory Park, Glory Park Avenue
Wooburn Green
HP10 0DF
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 5
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Piramal Critical care Limited
Suite 4, Heathrow Boulevard
West Drayton
UB7 0DQ
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 5
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Wockhardt UK Limited
Ash Road North, Wrexham Industrial Estate
Wrexham
LL13 9UF
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 5
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Cipla
Bourne Business Park, Addlestone
Addlestone
KT15 2LE
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 5
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 5
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Accord-UK Ltd
Whiddon Valley
Barnstaple
EX32 8NS
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 5
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 5 - Icatibant
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 10
Number of tenders received from SMEs: 4
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 10
Number of tenders received by electronic means: 10
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Celix Pharma Ltd.
4 Cullera Close
Middlesex
HA6 3SE
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 6
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 6 - Lanadelumab
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 0
Number of tenders received from tenderers from EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 1
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Takeda UK Ltd
1 Kingdom Street
London
W2 6BD
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section V: Award of contract
Lot No: 7
Contract No: CM/PHS/19/5583
Title: Hereditary Angioedema. Lot 7 - Berotralstat
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
20/06/2022
V.2.2) Information about tenders
Number of tenders received: 1
Number of tenders received from SMEs: 1
Number of tenders received from tenderers from EU Member States: 1
Number of tenders received from tenderers from non-EU Member States: 0
Number of tenders received by electronic means: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
BioCryst Ireland Limited
Harcourt Centre, Harcourt Road
Dublin
2D02 HW77
UK
NUTS: UK
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.4) Procedures for review
VI.4.1) Review body
The High Court
Strand
London
WC2A 2LL
UK
E-mail: generaloffice@administrativecourtoffice.justice.gov.uk
Internet address(es)
URL: https://www.gov.uk/courts-tribunals
VI.5) Date of dispatch of this notice
19/07/2022